A living WHO guideline on drugs to prevent covid-19

@article{Lamontagne2021ALW,
  title={A living WHO guideline on drugs to prevent covid-19},
  author={François Lamontagne and Thomas Agoritsas and Reed Alexander Siemieniuk and Bram Rochwerg and Jessica J. Bartoszko and Lisa M Askie and Helen Macdonald and Wagdy Amin and Fr{\'e}d{\'e}rique Jacquerioz Bausch and Erlina Burhan and Maurizio Cecconi and D. Chanda and Vu Quoc Dat and Bin Du and Heike Geduld and Patrick O. Gee and Harley Nerina and Madiha Hashimi and Beverley J. Hunt and Sushil Kumar Kabra and Seema Kanda and Leticia Kawano-Dourado and Yae-Jean Kim and Niranjan Kissoon and Arthur Kwizera and Yee Sin Leo and Imelda Mahaka and H{\'e}la Manai and Greta Mi{\~n}o and Emmanuel Fru Nsutebu and Natalia Y. Pshenichnaya and Nida Qadir and Shalini Sri Ranganathan and Saniya R Sabzwari and Rohit Sarin and Mike Sharland and Yinzhong Shen and Jo{\~a}o Paulo Souza and Miriam Songa Stegemann and S. Canales Ugarte and Sridhar Venkatapuram and Dubula Vuyiseka and Jacobus Preller and Romina Brignardello-Petersen and Elena Kum and Anila Qasim and Dena Zeraatkar and Andrew Owen and Gordon H. Guyatt and Lyubov Lytvyn and Janet Diaz and Per Olav Vandvik and Michael R. Jacobs},
  journal={BMJ},
  year={2021},
  volume={372}
}
Abstract Clinical question What is the role of drugs in preventing covid-19? Why does this matter? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. Recommendation The guideline… Expand
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
TLDR
The World Health Organization (WHO) living guideline on drugs to prevent COVID-19 should retract the advice to stop research on hydroxychloroquine chemoprophylaxis, should correct its errors, and should revise its guidance. Expand
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.
TLDR
In the three pre-exposure chemoprophylaxis RCTs evaluated in the guideline there were no deaths and only two COVID-19-related hospital admissions, and there was a mistake in the analysis of the number of discontinuations. Expand
Prophylaxis against covid-19: living systematic review and network meta-analysis
TLDR
This living network meta-analysis finds that hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Expand
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
TLDR
There is limited evidence for the benefit of ivermectin for COVID-19 treatment and prophylaxis, and most of this evidence is of low quality. Expand
Colchicine for the treatment of COVID-19.
TLDR
The effectiveness and safety of colchicine as a treatment option for COVID-19 in comparison to an active comparator, placebo, or standard care alone in any setting is assessed to maintain the currency of the evidence. Expand
Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal
TLDR
The quality of relevant COVID-19 clinical practice guidelines (CPGs) was not encouragingly high, but a few guidelines show Remdesivir may be beneficial for the patients, hydroxychloroquine +/– azithromycin may not, and there were more consistent suggestions regarding discharge management. Expand
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
TLDR
Patients with non-severe disease randomised to antiviral monoclonal antibodies had lower risk of hospitalisation than those who received placebo, except casirivimab-imdevimab, which may reduce mortality in patients who are seronegative. Expand
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
TLDR
This study, which is the largest to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophyllactic benefit of hydroXY chloroquine in the prevention of infection with SARS. Expand
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study
TLDR
Implementation of an early home treatment algorithm failed to accelerate recovery from major symptoms of COVID-19, but reduced the risk of hospitalisation and related treatment costs. Expand
A SIMPLE, HOME-THERAPY ALGORYTHM TO PREVENT HOSPITALIZATION OF COVID-19 PATIENTS: A RETROSPECTIVE OBSERVATIONAL MATCHED-COHORT STUDY
TLDR
Implementation of an early, home-treatment algorithm failed to accelerate recovery from major symptoms of COVID-19, but almost blunted the risk of hospitalization and related treatment costs. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 14 REFERENCES
A living WHO guideline on drugs for covid-19
TLDR
A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice, containing a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic cortiosteroids for non-severe patients. Expand
A living systematic review protocol for COVID-19 clinical trial registrations
TLDR
This living systematic review will provide a useful resource of COVID-19 clinical trial registrations for researchers in a rapidly evolving context and will allow prioritisation of research targets for individual patient data meta-analysis. Expand
Prophylaxis against covid-19: living systematic review and network meta-analysis
TLDR
This living network meta-analysis finds that hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Expand
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
TLDR
Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. Expand
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
TLDR
Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratory-confirmed Covid-19 or Covid -19-compatible illness among healthcare workers. Expand
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial
TLDR
In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Expand
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial
TLDR
First month follow-up analysis displayed that PrEP with hydroxychloroquine at low doses is safe and underpowered, and the study design deemed underpowered to evaluate any benefit regarding PrEP efficacy. Expand
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
TLDR
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid -19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. Expand
Guidelines International Network: Toward International Standards for Clinical Practice Guidelines
TLDR
G-I-N's proposed set of key components address panel composition, decision-making process, conflicts of interest, guideline objective, development methods, evidence review, basis of recommendations, ratings of evidence and recommendations, guideline review, updating processes, and funding. Expand
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
TLDR
This randomized controlled trial tests hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection. Expand
...
1
2
...